Pharmacogenomics of β-adrenergic receptors and their accessory signaling proteins in heart failure

Clinical and Translational Science

Volumn 1, Issue 3, 2008, Pages 255-262

  Dorn II, Gerald W ^a   Liggett, Stephen B ^b  

^a WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

receptors; Adrenergic; Heart failure; Receptors; Signal transduction

Indexed keywords

BETA ADRENERGIC RECEPTOR; BISOPROLOL; BUCINDOLOL; CARVEDILOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; PLACEBO;

AMINO ACID SUBSTITUTION; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; DOSE RESPONSE; GENOTYPE; HAPLOTYPE; HEART CATHETERIZATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE;

ANIMALS; G-PROTEIN-COUPLED RECEPTOR KINASE 5; HEART FAILURE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH;

EID: 67650519003     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2008.00059.x     Document Type: Review

References (47)

1. Lefkowitz RJ. Seven transmembrane receptors: Something old, something new. Acta Physiol. 2007; 190: 9-19.
2. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circ. 2000; 101: 558-569.
3. Bristow MR. Mechanistic and clinical rationales for using beta-blockers in heart failure. J Card Fail. 2000; 6: 8-14.
4. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human β1-adrenergic receptor. J Biol Chem. 1999; 274: 12670-12674.
5. Joseph SS, Lynham JA, Grace AA, Colledge WH, Kaumann AJ. Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared to Arg389-beta1-adrenoceptors. Br J Pharmacol. 2004; 142: 51-56.
6. Mialet-Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, Dorn GW, II, Liggett SB. Beta1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. 2003; 9: 1300-1305.
7. Wagoner LE, Craft LL, Zengel P, McGuire N, Rathz DA, Dorn GW I, Liggett SB. Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure. Am Heart J. 2002; 144: 840-846.
8. Sandilands AJ, Parameshwar J, Large S, Brown MJ, O'Shaughnessy KM. Confrmation of a role for the 389R>G beta-1 adrenoceptor polymorphism on exercise capacity in heart failure. Heart. 2005; 91: 1613-1614.
9. Bruck H, Leineweber K, Temme T, Weber M, Heusch G, Philipp T, Brodde OE. The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol. 2005; 46: 2111-2115.
10. Lobmeyer MT, Gong Y, Terra SG, Beitelshees AL, Langaee TY, Pauly DF, Schofeld RS, Hamilton KK, Herbert PJ, Adams KF, Jr., Hill JA, Aranda JM, Jr., Johnson JA. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics. 2007; 17: 277-282.
11. Molenaar P, Chen L, Semmler AB, Parsonage WA, Kaumann AJ. Human heart beta-adrenoceptors: Beta1-adrenoceptor diversifcation through "affnity states" and polymorphism. Clin Exp Pharmacol Physiol. 2007; 34: 1020-1028.
12. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Wagoner LE, Abraham WT, Anderson JL, Carlquist JF, Krause-Steinrauf HJ, Lazzeroni LC, Port JD, Lavori PW, Bristow MR. A polymorphism within a conserved beta1-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006; 103: 11288-11293.
13. White HL, De Boer RA, Maqbool A, Greenwood D, van Veldhuisen DJ, Cuthbert R, Ball SG, Hall AS, Balmforth AJ. An evaluation of the beta1-adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: A MERIT-HF sub-study. Eur J Heart Failure. 2003; 5: 463-468.
14. Shin J, Lobmeyer MT, Gong Y, Zineh I, Langaee TY, Yarandi H, Schofield RS, Aranda JM, Jr., Hill JA, Pauly DF, Johnson JA. Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol. 2007; 99: 250-255.
15. de Groote P, Lamblin N, Helbecque N, Mouquet F, Mc FE, Hermant X, Amouyel P, Dallongeville J, Bauters C. The impact of beta-adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure. Eur J Heart Fail. 2005; 7: 966-973.
16. Sehnert AJ, Daniels SE, Elashoff M, Wingrove JA, Burrow CR, Horne B, Muhlestein JB, Donahue M, Liggett SB, Anderson JL, Kraus WE. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol and metoprolol. J Am Coll Cardiol. 2008; 52: 644-651.
17. Rathz DA, Brown KM, Kramer LA, Liggett SB. Amino acid 49 polymorphisms of the human beta 1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol. 2002; 39: 155-160.
18. Levin MC, Marullo S, Muntaner O, Andersson B, Magnusson Y. The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem. 2002; 277: 30429-30435.
19. Hassan M, York KM, Li H, Li Q, Gong Y, Langaee TY, Fillingim RB, Johnson JA, Sheps DS. Association of beta1-adrenergic receptor genetic polymorphism with mental stress-induced myocardial ischemia in patients with coronary artery disease. Arch Intern Med. 2008; 168: 763-770.
20. Magnusson Y, Levin MC, Eggertsen R, Nystrom E, Mobini R, Schaufelberger M, Andersson B. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther. 2005; 78: 221-231.
21. Defoor J, Martens K, Zielinska D, Matthijs G, Van Nerum H, Schepers D, Fagard R, Vanhees L. The CAREGENE study: Polymorphisms of the beta1-adrenoceptor gene and aerobic power in coronary artery disease. Eur Heart J. 2006; 27: 808-816.
22. Forleo C, Resta N, Sorrentino S, Guida P, Manghisi A, De Luca V, Romito R, Iacoviello M, De Tommasi E, Troisi F, Rizzon B, Guanti G, Rizzon P, Pitzalis MV. Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med. 2004; 117: 451-458.
23. Green SA, Cole G, Jacinto M, Innis M, Liggett SB. A polymorphism of the human beta2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem. 1993; 268: 23116-23121.
24. Turki J, Lorenz JN, Green SA, Donnelly ET, Jacinto M, Liggett SB. Myocardial signalling deffects and impaired cardiac function of a human beta2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci USA. 1996; 93: 10483-10488.
25. McGraw DW, Forbes SL, Kramer LA, Liggett SB. Polymorphisms of the 59 leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest. 1998; 102: 1927-1932.
26. Green S, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochem. 1994; 33: 9414-9419.
27. Shin J, Johnson JA. Beta-blocker pharmacogenetics in heart failure. Heart Fail Rev. 2008 In press.
28. Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy. 2007; 27: 874-887.
29. Engelhardt S. Alternative signaling: Cardiomyocyte beta1-adrenergic receptors signal through EGFRs. J Clin Invest. 2007; 117: 2396-2398.
30. Lynch RA, Wagoner LE, Li S, Sparks L, Molkentin J, Dorn GW II. Novel and nondetected human signaling protein polymorphisms. Physiol Genomics. 2002; 10: 159-168.
31. Jia H, Hingorani AD, Sharma P, Hopper R, Dickerson C, Trutwein D, Lloyd DD, Brown MJ. Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. Hypertension. 1999; 34: 8-14.
32. Weinstein LS, Chen M, Xie T, Liu J. Genetic diseases associated with heterotrimeric G proteins. Trends Pharmacol Sci. 2006; 27: 260-266.
33. Spiegel AM. Albright's hereditary osteodystrophy and deffective G proteins. N Engl J Med. 1990; 322: 1461-1462.
34. Peters BJ, Maitland-van der Zee AH, Stricker BH, van Wieren-de Wijer DB, de Boer A, Kroon AA, de Leeuw PW, Schiffers P, Janssen RG, van Duijn CM, Klungel OH. Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant. Pharmacogenet Genomics. 2008; 18: 631-636.
35. Siffert W. Molecular genetics of G proteins and atherosclerosis risk. Basic Res Cardiol. 2001; 96: 606-611.
36. Kiani JG, Saeed M, Parvez SH, Frossard PM. Association of G-protein beta-3 subunit gene (GNB3) T825 allele with type II diabetes. Neuro Endocrinol Lett. 2005; 26: 87-88.
37. Meirhaeghe A, Cottel D, Amouyel P, Dallongeville J. Lack of association between certain candidate gene polymorphisms and the metabolic syndrome. Mol Genet Metab. 2005; 86: 293-299.
38. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, Sharma AM, Ritz E, Wichmann HE, Jakobs KH, Horsthemke B. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet. 1998; 18: 45-48.
39. Riddle EL, Schwartzman RA, Bond M, Insel PA. Multi-tasking RGS proteins in the heart: The next therapeutic target? Circ Res. 2005; 96: 401-411.
40. Riddle EL, Rana BK, Murthy KK, Rao F, Eskin E, O'Connor DT, Insel PA. Polymorphisms and haplotypes of the regulator of G protein signaling-2 gene in normotensives and hypertensives. Hypertension. 2006; 47: 415-420.
41. Metaye T, Gibelin H, Perdrisot R, Kraimps JL. Pathophysiological roles of G-protein-coupled receptor kinases. Cell Signal. 2005; 17: 917-928.
42. Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, Diwan A, Martini JS, Sparks L, Parekh RR, Spertus JA, Koch WJ, Kardia SL, Dorn GW II. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med. 2008; 14: 510-517.
43. Wang WC, Mihlbachler KA, Bleecker ER, Weiss ST, Liggett SB. A polymorphism of G-protein coupled receptor kinase5 alters agonist-promoted desensitization of beta2-adrenergic receptors. Pharmacogenet Genomics. 2008; 18: 729-732.
44. Yancy CW. Heart failure in African Americans. Am J Cardiol. 2005; 96: 3i-12i.
45. Ribas C, Penela P, Murga C, Salcedo A, Garcia-Hoz C, Jurado-Pueyo M, Aymerich I, Mayor F, Jr. The G protein-coupled receptor kinase (GRK) interactome: Role of GRKs in GPCR regulation and signaling. Biochim Biophys Acta. 2007; 1768: 913-922.
46. Lohmueller KE, Wong LJ, Mauney MM, Jiang L, Felder RA, Jose PA, Williams SM. Patterns of genetic variation in the hypertension candidate gene GRK4: Ethnic variation and haplotype structure. Ann Hum Genet. 2006; 70: 27-41.
47. Felder RA, Sanada H, Xu J, Yu PY, Wang Z, Watanabe H, Asico LD, Wang W, Zheng S, Yamaguchi I, Williams SM, Gainer J, Brown NJ, Hazen-Martin D, Wong LJ, Robillard JE, Carey RM, Eisner GM, Jose PA. G protein-coupled receptor kinase 4 gene variants in human essential hypertension. Proc Natl Acad Sci USA. 2002; 99: 3872-3877.